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mechanisms. Isolation of Mycoplasma pneu- 
moniae from extrapulmonary sites provides evi- 
dence of a more invasive role in extrapulmonary 
manifestations, indicating that the organism may 
spread more frequently than thought. Demon- 
stration of Mycoplasma pneumoniae outside the 
respiratory tract is hampered by the organism's 
fastidious nature, the invasive procedures re- 
quired and the lack of thorough research. 
Our case shows that some cases diagnosed as id- 
iopathic pericarditis could have a mycoplasmal 
etiology, even in the absence of serological docu- 
mentation. Large pericardial effusions, particu- 
larly in immunosuppressed patients or those with 
previous cardiac surgery, may be clues for suspi- 
cion of mycoplasmal pericarditis. Appropriate 
treatment with tetracycline or erythromycin 
might be effective in curing this severe complica- 
tion of Mycoplasma pneumoniae infection. 
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Cryptococcal Meningitis Following 
Fludarabine Treatment for Chronic 
Lymphocytic Leukemia 
Fludarabine (9q3-D-arabinofuranosyl-2-fluorade- 
nine) is a purine antimetabolite that is highly active 
in the treatment of low-grade lymphoma, chronic 
lymphocytic leukemia and Waldenstr6m's macro- 
globulinemia. The use of fludarabine in first- and 
second-line treatment has resulted in high response 
rates (1). Chronic administration of fludarabine 
causes lymphocytopenia, leading to decreased 
numbers of T-lymphocytes and, to a lesser extent, 
B-lymphocytes (2). It is hypothesized that fludara- 
bine induces deficiency of the cell-mediated immu- 
nity, thereby predisposing to opportunistic infec- 
tions (3). Opportunistic microorganisms, which are 
found characteristically in patients with impaired 
cellular immunity, may cause severe infections in 
fiudarabine-treated patients (4, 5). We describe 
here a patient with chronic lymphocytic leukemia 
who was treated with fludarabine and who sub- 
sequently experienced a primary episode of crypto- 
coccal meningitis. 
A 47-year-old man who had developed chronic 
lymphocytic leukemia, Binet stage III, 10 years 
previously was treated from 1988 to 1993 with 
several cycles of chlorambucil and cyclophos- 
phamide/prednisone. In 1993 he was treated with 
four cycles of fludarabine (25 mg/m 2 x 5, total of 
975 mg) and prednisone. During the last course of 
fludarabine he experienced an unexplained epi- 
sode of pulmonary infection with dyspnea and 
interstitial infiltrates in both lungs. No causative 
organisms were found in the bronchoalveolar l v- 
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age fluid; microscopic preparations and cultures 
for Pneumocystis carinii and cytomegalovirus 
were negative. 
Four months after the last dose of fludarabine was 
administered, the patient was admitted to hospi- 
tal for treatment with cyclophosphamide, adri- 
amycine, vincristine and prednisone because of 
progression of the chronic lymphocytic leukemia 
to an intermediate-grade non-Hodgkin's lym- 
phoma. One week after this treatment he re- 
ported back to the hospital with fever (40~ 
nausea and vomiting. At this time no headache 
was reported. Anterior cervical and axillary and 
inguinal adenopathy was present. Neurological 
and physical examination was otherwise normal; 
there were no signs of meningism. Laboratory ana- 
lysis revealed a leukocyte count of 6,400 cells/mm 3 
(98.6 % lymphocytes). The erythrocyte sedimen- 
tation rate was 114 mm/h. 
A chest radiograph showed a dense infiltrate in 
the left lower lobe, and empiric antibiotic therapy 
was started. Fever, however, remained high, and 
after seven days the patient developed a mod- 
erate headache. At this time antibiotic therapy 
was discontinued. After ten days Cryptococcus 
neoformans grew from blood cultures taken at ad- 
mission. The serum cryptococcal ntigen titer was 
1:524,288. A lumbar puncture was performed, and 
encapsulated yeasts were seen in the India ink- 
stained specimen. The CSF cryptococcal ntigen 
titer was 1:2,048. Cryptococcus neoformans was 
cultured from the CSE Direct ophthalmoscopy 
showed bilateral papilloedema (unfortunately, 
the lumbar opening pressure was not measured). 
Treatment with amphotericin B (0.7 mg/kg) was 
started. The patient's temperature and headache 
did not improve, and Cryptococcus neoformans 
was still cultured from the CSF after two weeks of 
treatment with amphotericin B. Flucytosine 
(5 mg/day) was added to the treatment regimen, 
and in the following three weeks the patient's con- 
dition slowly improved. The cryptococcal ntigen 
titers in serum and in CSF had decreased to 
1:2,048 and 1:128, respectively. He was discharged 
from the hospital on fluconazole (400 mg/day) as 
maintenance therapy. In the months following his 
discharge, the patient received several courses of 
chemotherapy. Despite this, his condition deteri- 
orated and he died later due to pulmonary insuffi- 
ciency. At obduction Aspergillus fumigatus was 
cultured from both lungs. There were no indica- 
tions of persistent cryptococcal infection. 
We describe a patient with cryptococcal menin- 
gitis after treatment with fludarabine and predni- 
sone. Fludarabine is a purine antimetabolite 
introduced in the early 1980s and used more ex- 
tensively today in the treatment of chronic lym- 
phocytic leukemia and non-Hodgkin's lym- 
phoma. High response rates (> 50 %) are de- 
scribed after previous treatment with other regi- 
mens, and even higher response rates have been 
observed when fludarabine was used as initial 
treatment (overall response 79 %, with 75 % of 
the patients achieving complete remission) (4). 
The major complication during fludarabine ther- 
apy is infection, often with opportunistic microor- 
ganisms, especially when fludarabine is used in 
combination with prednisone (4, 5). This is prob- 
ably due to the effects of fludarabine on the 
different subsets of lymphocytes. Lymphocyto- 
penia develops within a few days after adminis- 
tration of fludarabine (2). While the reduction of 
B-lymphocytes is relatively small, with an average 
of 50 %, the T-lymphocyte counts decrease by 
about 90 % (6). Both CD4+ and CD8+ subpopu- 
lations decrease substantially, but CD4+ reduc- 
tion is more substantial, resulting in a reversal of 
the CD4+:CD8+ ratio. This phenomenon is also 
seen in advanced stages of chronic lymphocytic 
leukemia and in HIV-infected patients (6). The 
reduction of CD4+ lymphocytes and the reversal 
of the CD4+:CD8+ ratio is thought o result in in- 
creased susceptibility o opportunistic nfections. 
Pneumocystis carinii, Listeria monocytogenes and
cytomegalovirus have been reported in patients 
treated with fludarabine with or without predni- 
sone (3-5, 7). Sometimes the same features are 
seen in patients without underlying diseases. 
Cryptococcal infections are described in these 
patients, too, underscoring the importance of this 
phenomenon (8, 9). 
As far as we know, ours is the first patient pre- 
sented in the literature with cryptococcal menin- 
gitis after fludarabine therapy. Although crypto- 
coccal meningitis was diagnosed only four 
months after the last dose of fludarabine, it is very 
likely that our patient acquired the infection as a 
consequence of this treatment. We have two rea- 
sons for this assumption. First, as stated pre- 
viously, it is likely that the cellular immunosup- 
pression caused by fludarabine continues to exist 
for months or even years after therapy is stopped 
(5). During this period cryptococcosis may have 
been clinically dormant and not specific, as occurs 
in AIDS patients (10). Second, during his last 
course of fludarabine, our patient had an episode 
of pneumonia for which no causative organism 
was found. It is possible that this episode was also 
caused by Cryptococcus neoformans (although 
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cryptococcal antigen titers in serum samples 
drawn at that time remained negative when 
tested 4 months later). We presume that under 
continued immunosuppression after fludarabine 
therapy, followed by further depression of the im- 
munity caused by the cyclophosphamide, adri- 
amycine, vincristine and prednisone regimen, the 
infection spread to the central nervous ystem. 
Our patient's case history shows that opportunis- 
tic infections, including cryptococcal meningitis, 
should be considered in patients who have been 
treated with fludarabine several months pre- 
viously, even when headache is not reported. 
Cryptococcosis can be easily diagnosed in these 
patients by determination of serum cryptococcal 
antigen titers. 
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An Imported Fatal Case of Diphtheria in Italy 
Confirmed diphtheria cases have been very rare 
in Italy for many years, and biochemical charac- 
terization or molecular biotyping of toxigenic Co- 
rynebacterium diphtheriae has not previously 
been described. We report the biological charac- 
teristics of a strain of Corynebacteriurn diph- 
theriae that was also biotyped by molecular 
methods to define its origin and to establish 
whether it was imported or indigenous. 
In December 1993, a 38-year-old Peruvian woman, 
an illegal immigrant o Italy, died of diphtheria 
within one day of admission to a hospital in 
Rome. The woman had been febrile for six days 
before seeking treatment for acute respiratory 
distress. Autopsy and microbiological examina- 
tion confirmed the initial suspicion of diphtheria 
at admission. A biopsy of the mucous membranes 
from the soft palate and pharyngeal wall, taken 
during tracheostomy (performed immediately 
after admission), was examined for the presence 
of Corynebacterium diphtheriae, which was found 
in association with Streptococcus rnutans. The iso- 
late of Corynebacterium diphtheriae was iden- 
tified by microscopic morphology and biotyping 
(API Coryne, bioM6rieux, France) which desig- 
nated it as Corynebacterium diphtheriae var. 
gravis. Toxigenicity of Corynebacterium diph- 
theriae was determined using a DNA probe (T21) 
specific for the diphtheria toxin gene (1) and by 
the in vivo guinea pig subcutaneous virulence test 
(2). Southern blot hybridization of BamHI- 
restricted Corynebacteriurn diphtheriae DNA 
